Literature DB >> 32229611

Chronic Lymphocytic Leukemia.

Nicholas Chiorazzi1, Shih-Shih Chen1, Kanti R Rai2.   

Abstract

Patients with chronic lymphocytic leukemia can be divided into three categories: those who are minimally affected by the problem, often never requiring therapy; those that initially follow an indolent course but subsequently progress and require therapy; and those that from the point of diagnosis exhibit an aggressive disease necessitating treatment. Likewise, such patients pass through three phases: development of the disease, diagnosis, and need for therapy. Finally, the leukemic clones of all patients appear to require continuous input from the exterior, most often through membrane receptors, to allow them to survive and grow. This review is presented according to the temporal course that the disease follows, focusing on those external influences from the tissue microenvironment (TME) that support the time lines as well as those internal influences that are inherited or develop as genetic and epigenetic changes occurring over the time line. Regarding the former, special emphasis is placed on the input provided via the B-cell receptor for antigen and the C-X-C-motif chemokine receptor-4 and the therapeutic agents that block these inputs. Regarding the latter, prominence is laid upon inherited susceptibility genes and the genetic and epigenetic abnormalities that lead to the developmental and progression of the disease.
Copyright © 2021 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 32229611      PMCID: PMC7849345          DOI: 10.1101/cshperspect.a035220

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  8 in total

1.  Activated CLL cells regulate IL-17F-producing Th17 cells in miR155-dependent and outcome-specific manners.

Authors:  Byeongho Jung; Gerardo Ferrer; Pui Yan Chiu; Rukhsana Aslam; Anita Ng; Florencia Palacios; Michael Wysota; Martina Cardillo; Jonathan E Kolitz; Steven L Allen; Jacqueline C Barrientos; Kanti R Rai; Nicholas Chiorazzi; Barbara Sherry
Journal:  JCI Insight       Date:  2022-06-22

2.  In silico investigations identified Butyl Xanalterate to competently target CK2α (CSNK2A1) for therapy of chronic lymphocytic leukemia.

Authors:  Suliman A Alsagaby; Danish Iqbal; Iqrar Ahmad; Harun Patel; Shabir Ahmad Mir; Yahya Awaji Madkhali; Atif Abdulwahab A Oyouni; Yousef M Hawsawi; Fahad A Alhumaydhi; Bader Alshehri; Wael Alturaiki; Bader Alanazi; Manzoor Ahmad Mir; Waleed Al Abdulmonem
Journal:  Sci Rep       Date:  2022-10-21       Impact factor: 4.996

3.  Chronic Lymphocytic Leukemia in Neurofibromatosis Type 1 Patients: Case Report and Literature Review of a Rare Occurrence.

Authors:  Philip R Cohen
Journal:  Cureus       Date:  2021-04-02

Review 4.  Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib.

Authors:  Ankit Shah; Jacqueline C Barrientos
Journal:  Onco Targets Ther       Date:  2021-03-25       Impact factor: 4.147

Review 5.  Immunoglobulin Gene Sequence as an Inherited and Acquired Risk Factor for Chronic Lymphocytic Leukemia.

Authors:  Moumita Datta; Hassan Jumaa
Journal:  Cancers (Basel)       Date:  2022-06-21       Impact factor: 6.575

6.  Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia.

Authors:  Matthew Kaufman; Xiao-Jie Yan; Wentian Li; Emanuela M Ghia; Anton W Langerak; Laura Z Rassenti; Chrysoula Belessi; Neil E Kay; Frederic Davi; John C Byrd; Sarka Pospisilova; Jennifer R Brown; Mark Catherwood; Zadie Davis; David Oscier; Marco Montillo; Livio Trentin; Richard Rosenquist; Paolo Ghia; Jacqueline C Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti R Rai; Kostas Stamatopoulos; Thomas J Kipps; Donna Neuberg; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2022-07-12       Impact factor: 5.738

Review 7.  AID in Chronic Lymphocytic Leukemia: Induction and Action During Disease Progression.

Authors:  Pablo Oppezzo; Marcelo Navarrete; Nicholas Chiorazzi
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

8.  Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL.

Authors:  Gerardo Ferrer; Byeongho Jung; Pui Yan Chiu; Rukhsana Aslam; Florencia Palacios; Andrea Nicola Mazzarello; Stefano Vergani; Davide Bagnara; Shih-Shih Chen; Sophia Yancopoulos; Aliki Xochelli; Xiao-Jie Yan; Jan A Burger; Jacqueline C Barrientos; Jonathan E Kolitz; Steven L Allen; Kostas Stamatopoulos; Kanti R Rai; Barbara Sherry; Nicholas Chiorazzi
Journal:  Leukemia       Date:  2021-05-02       Impact factor: 12.883

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.